Day 3 Blockbuster: Corona Remedies IPO 15x Oversubscribed, GMP Hints Massive Listing Pop – Jump In?

Open Dec 8-10, this 100% OFS raises ₹655 cr from promoters/shareholders (no fresh capital). Price band: ₹1008-1062 (lot: 14 shares, min ₹14,868 retail). Listing Dec 15 on BSE/NSE. FY25: Revenue ₹1196 cr (+growth), PAT ₹149 cr; focuses formulations in acute/chronic therapies.​

Key Highlights

Subscription Status: Day 3 ~15.70x overall; Retail 5.62-6.77x, NII 12-28x, QIB 1.76x (Day 2 data; final pending).​

GMP Buzz: ₹262-₹330 (24-31% premium); expected listing ₹1324-1392 vs upper band.​

Financials: EBITDA ₹246 cr; diversified portfolio, strong mfg, but key brand/regulatory risks noted.​

Investor Advice: Apply for listing gains (strong demand/GMP); long-term cautious on valuation/OFS structure.​

Pharma momentum roars—final hours to bid!

Sources: Economic Times, Moneycontrol, IPOWatch, Chittorgarh, Zerodha.​